2013 FDA Approval Rates Suggest Record Year for Post-Launch Success
A focus on hard to treat or specialist diseases is set to result in record post-launch sales for new drugs in 2013, according to newly-released report, “FDA Approval Rates: Niche Products Driving Record Success,” from EP Vantage, the editorial arm of Evaluate.
Although the total tally of approved drugs and biologics for 2013 is not forecast to match last year’s record of 43, the combined US sales for this year’s approved products could surpass $18 billion, 5 years after launch. The report, based on market intelligence and analysis from EvaluatePharma, can be downloaded by clicking here.
Key Findings:
• From 1 January to 11 November 2013, FDA approved 27 new compounds with another seven hopefuls awaiting approval.
• Of the 27 drugs approved so far, combined fifth-year US sales are forecast to reach $13.9 billion.
• Assuming all products awaiting regulatory decisions get a green light, 2013’s fifth-year sales could total $18.7 billion, breaking the 2012 record of $16.4 billion.
• Tecfidera ranks No. 1 among top five approvals of 2013 (January to November, 11) with sales estimated at $2.9 billion by 2018.
• If approved in 2013, Gilead Sciences’ sofosbuvir stands to become this year’s most valuable new molecule, with fifth-year US sales estimated at almost $3 billion.
“Increased efforts on the part of FDA to speed up drug development and also companies choosing to expand into rare diseases or niche patient populations is having a big impact on productivity,” said Lisa Urquhart, EP Vantage Editor. “One example of this is the earlier-than-expected approval of Roche’s Gazyva, which was the first drug to reach the market under the breakthrough therapy designation scheme. We have also seen the approval of big ticket drugs such as Tecfidera this year and are still waiting one of the industry’s biggest drugs, sofosbuvir. Barring any upsets this will make 2013 a year to remember in terms of future blockbuster sales.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance